Fabrizio Stocchi Selected Research

ropinirole (Requip)

6/2011	PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease.
12/2009	The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease.
10/2008	Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study.
7/2003	Dual dopamine agonist treatment in Parkinson's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fabrizio Stocchi Research Topics

Disease

110	Parkinson Disease (Parkinson's Disease) 12/2024 - 09/2002
32	Dyskinesias (Dyskinesia) 05/2024 - 09/2002
8	Dementia (Dementias) 12/2023 - 01/2019
6	Alzheimer Disease (Alzheimer's Disease) 01/2023 - 01/2020
6	Fatigue 02/2022 - 05/2011
5	Disease Progression 04/2024 - 01/2003
4	Tremor (Tremors) 04/2024 - 11/2012
4	Cognitive Dysfunction 10/2023 - 06/2012
4	Constipation 01/2023 - 12/2015
4	Deglutition Disorders (Dysphagia) 01/2023 - 12/2009
4	Pain (Aches) 02/2022 - 01/2017
3	Sleep Initiation and Maintenance Disorders (Insomnia) 11/2020 - 11/2013
2	REM Sleep Behavior Disorder 04/2024 - 09/2020
2	Injection Site Reaction 03/2024 - 11/2021
2	Psychotic Disorders (Schizoaffective Disorder) 10/2023 - 09/2020
2	Nausea 10/2023 - 01/2016
2	Major Depressive Disorder (Major Depressive Disorders) 01/2021 - 11/2012
2	Parkinsonian Disorders (Parkinsonism) 06/2015 - 12/2009
2	Hallucinations (Hallucination) 11/2013 - 03/2003
1	Chronic Renal Insufficiency 10/2023
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 10/2023
1	Neurobehavioral Manifestations 09/2023
1	Anhedonia 09/2023
1	Dysbiosis 01/2023
1	Infections 01/2023
1	Movement Disorders (Movement Disorder) 02/2022
1	Tauopathies 01/2022
1	Headache (Headaches) 01/2022
1	Seizures (Absence Seizure) 01/2021
1	Heart Failure 09/2020
1	Disorders of Excessive Somnolence (Hypersomnia) 09/2020
1	Orthostatic Hypotension (Postural Hypotension) 09/2020
1	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 09/2020
1	Nocturia 03/2020
1	Inflammation (Inflammations) 01/2020
1	Back Pain (Backache) 01/2020
1	Prodromal Symptoms 01/2019

Drug/Important Bio-Agent (IBA)

61	Levodopa (L Dopa)FDA LinkGeneric 12/2024 - 09/2002
14	Carbidopa (Lodosyn)FDA LinkGeneric 03/2024 - 06/2005
12	Dopamine Agonists (Dopamine Agonist)IBA 01/2023 - 07/2003
8	Apomorphine FDA Link 11/2023 - 05/2003
6	opicaponeIBA 11/2022 - 07/2017
6	levodopa methyl esterIBA 12/2019 - 01/2007
6	rasagiline (Azilect)FDA Link 10/2016 - 11/2008
5	safinamideIBA 02/2022 - 01/2012
5	Dopamine Receptors (Dopamine Receptor)IBA 05/2011 - 07/2006
4	SynucleinsIBA 04/2024 - 01/2017
4	Antidepressive Agents (Antidepressants)IBA 12/2023 - 01/2017
4	levodopa drug combination carbidopa (Nakom)FDA LinkGeneric 10/2023 - 09/2010
4	Dopamine (Intropin)FDA LinkGeneric 09/2020 - 07/2010
4	ropinirole (Requip)FDA LinkGeneric 06/2011 - 07/2003
3	Monoclonal AntibodiesIBA 04/2024 - 01/2022
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2003
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2009
3	TabletsIBA 01/2015 - 07/2010
3	entacapone (Comtan)FDA Link 07/2013 - 04/2009
3	Dopamine Agents (Dopaminergic Agents)IBA 05/2011 - 07/2006
2	catechol (pyrocatechol)IBA 10/2023 - 10/2018
2	TransferasesIBA 10/2023 - 10/2018
2	BenserazideIBA 10/2023 - 03/2020
2	mesoglycanIBA 03/2022 - 11/2021
2	istradefyllineIBA 01/2021 - 11/2018
2	Carboxy-LyasesIBA 01/2021 - 12/2018
2	EnzymesIBA 11/2020 - 12/2009
2	Antipsychotic Agents (Antipsychotics)IBA 11/2020 - 12/2009
2	2- (2- furanyl)- 7- (2- (4- (4- (2- methoxyethoxy)phenyl)- 1- piperazinyl)ethyl)- 7H- pyrazolo(4,3- e)(1,2,4)triazolo(1,5- c)pyrimidine- 5- amineIBA 06/2017 - 12/2015
2	Adenosine (Adenocard)FDA LinkGeneric 06/2017 - 12/2015
2	mavoglurantIBA 01/2016 - 11/2013
2	Cabergoline FDA LinkGeneric 06/2015 - 07/2003
2	sirioIBA 01/2015 - 07/2010
2	ProdrugsIBA 07/2010 - 01/2007
2	DNA (Deoxyribonucleic Acid)IBA 01/2005 - 03/2003
1	Monoamine Oxidase (MAO)IBA 04/2024
1	SolutionsIBA 03/2024
1	Nerve Growth Factors (Neurotrophins)IBA 12/2023
1	Apolipoproteins AIBA 01/2023
1	Aromatic Amino Acid Decarboxylase InhibitorsIBA 01/2023
1	Catechol O-Methyltransferase (Methyltransferase, Catechol)IBA 11/2022
1	Glutamic Acid (Glutamate)FDA Link 02/2022
1	Hyaluronic Acid (Hyaluronan)IBA 02/2022
1	Amyloid beta-PeptidesIBA 01/2022
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2022
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 01/2021
1	BenzodiazepinesIBA 01/2021
1	Amyloid (Amyloid Fibrils)IBA 11/2020
1	CytochromesIBA 09/2020
1	hydroxide ionIBA 09/2020
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2020
1	amsonic acid (DAS)IBA 05/2019
1	Cholinergic Agents (Cholinergics)IBA 01/2019

Therapy/Procedure

35	Therapeutics 05/2024 - 09/2002
5	Activities of Daily Living (ADL) 01/2020 - 03/2010
3	Electrodes (Electrode) 01/2023 - 12/2022
2	Deep Brain Stimulation 11/2023 - 07/2006
1	Subcutaneous Infusions 03/2024
1	Renal Dialysis (Hemodialysis) 10/2023
1	Intravenous Infusions 01/2022
1	Hormone Replacement Therapy (Therapy, Hormone Replacement) 09/2020
1	Duration of Therapy 12/2019
1	Oral Administration 01/2019